Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

N.V. Rajeshkumar

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5083345144. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
63
Papers, trials and grants by year

2011: 5 papers · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper

Papers 19

  1. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  2. Direct Interactions With Cancer-Associated Fibroblasts Lead to Enhanced Pancreatic Cancer Stem Cell Function. Co-author DOI 10.1097/mpa.0000000000001249↗
  3. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-1973↗
  4. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Co-author DOI 10.1158/1078-0432.ccr-17-1115↗
  5. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0180181↗
  6. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Co-author DOI 10.21037/jgo.2017.09.05↗
  7. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Co-author DOI 10.1038/bjc.2016.215↗
  8. Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Co-author DOI 10.1158/0008-5472.can-15-0108↗
  9. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Co-author DOI 10.1074/mcp.m114.038547↗
  10. A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9822-x↗
  11. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Last author DOI 10.1016/j.canlet.2013.01.054↗
  12. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9818-6↗
  13. Conceptual framework for cutting the pancreatic cancer fuel supply. First author DOI 10.1158/1078-0432.ccr-12-0041↗
  14. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Last author DOI 10.1158/1535-7163.mct-12-0017↗
  15. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Co-author DOI 10.1158/1078-0432.ccr-10-2580↗
  16. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic … Co-author DOI 10.1158/1078-0432.ccr-11-0341↗
  17. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. First author DOI 10.1158/1535-7163.mct-10-0893↗
  18. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Co-author DOI 10.1200/jco.2011.36.5742↗
  19. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Co-author DOI 10.4161/cbt.12.7.16475↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 17 shared papers, 2011–2020 · strength 0.78
  2. Manuel M. Hidalgo · 13 shared papers, 2011–2017 · strength 0.45
  3. Shinichi Yabuuchi · 7 shared papers, 2012–2020 · strength 0.39
  4. Zeshaan A. Rasheed · 6 shared papers, 2011–2020 · strength 0.31
  5. Daniel A. Laheru · 6 shared papers, 2011–2020 · strength 0.23
  6. Asma Begum · 3 shared papers, 2017–2020 · strength 0.23
  7. Daniel D. Von Hoff · 4 shared papers, 2011–2020 · strength 0.22
  8. Roeland F. de Wilde · 4 shared papers, 2012–2020 · strength 0.20
  9. William H. Matsui · 4 shared papers, 2011–2019 · strength 0.19
  10. Ramesh K. Ramanathan · 3 shared papers, 2011–2020 · strength 0.17
  11. Ana De Jesus‐Acosta · 3 shared papers, 2011–2020 · strength 0.17
  12. Chi Van Dang · 3 shared papers, 2012–2017 · strength 0.15
  13. Vesselin R. Penchev · 2 shared papers, 2017–2019 · strength 0.14
  14. Christopher Lee Wolfgang · 2 shared papers, 2017–2019 · strength 0.14
  15. Florencia M. McAllister · 2 shared papers, 2012–2020 · strength 0.12
  16. Jurre J. Kamphorst · 2 shared papers, 2015–2017 · strength 0.11
  17. Joshua D. Rabinowitz · 2 shared papers, 2015–2017 · strength 0.11
  18. Peter James O'Dwyer · 1 shared paper, 2020 · strength 0.09
  19. Robert A. Anders · 1 shared paper, 2020 · strength 0.09
  20. Bhavina D O Batukbhai · 1 shared paper, 2020 · strength 0.09
  21. Lei Zheng · 1 shared paper, 2020 · strength 0.09
  22. Michael Goggins · 1 shared paper, 2019 · strength 0.09
  23. Anne Le · 2 shared papers, 2012–2015 · strength 0.09
  24. Ralph H. Hruban · 3 shared papers, 2011–2014 · strength 0.08
  25. Victoria H. Cruz · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.